1-6 of 6
Ashish Gautam, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study

Joseph M. Connors, MD, Anas Younes, MD, Andrea Gallamini, MD, Stephen M. Ansell, MD PhD, Won-Seog Kim, Ranjana H Advani, MD, Nancy L. Bartlett, MD, David J. Straus, MD, Anna Sureda, MD, Martin Hutchings, MD PhD, Monika Dlugosz-Danecka, MD PhD, Gerald Engley, PharmD, Keenan Fenton, Rachael Liu, PhD, Harry Miao, MD, Hina Jolin, Pharm D, Ashish Gautam, PhD MBA, John Radford, MD FRCP
Journal: Blood
Blood (2018) 132 (Supplement 1): 2904.
https://doi.org/10.1182/blood-2018-99-118828
Published: 2018
Journal Articles

Resolution of Peripheral Neuropathy (PN) in Patients Who Received A+AVD or ABVD in the Phase 3 ECHELON-1 Trial

John Radford, MD FRCP, Joseph M. Connors, MD, Anas Younes, MD, Andrea Gallamini, MD, Stephen M. Ansell, MD PhD, Won Seog Kim, MD PhD, Ajay K. Gopal, MD, Mark S Kaminski, MD, June Won Cheong, MDPhD, Ian W. Flinn, MD PhD, Nagesh Kalakonda, MD, Ruth Pettengell, MD, Monika Dlugosz-Danecka, MD PhD, Gerald Engley, PharmD, Keenan Fenton, Rachael Liu, PhD, Indra Purevjal, Harry Miao, MD, Ashish Gautam, PhD MBA, John Kuruvilla, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2921.
https://doi.org/10.1182/blood-2018-99-111893
Published: 2018
Journal Articles

Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study

Andrew M. Evens, DO, MSc, Joseph M. Connors, MD, Anas Younes, MD, Stephen M. Ansell, MD PhD, Won Seog Kim, MD PhD, John Radford, MD FRCP, Tatyana A. Feldman, MD, Joseph Tuscano, Kerry J Savage, BSc, MD MSc, Yasuhiro Oki, MD, Andrew P. Grigg, MBBS, FRACP, FRCPA, MD, Christopher Pocock, MD PhD, Monika Dlugosz-Danecka, MD PhD, Keenan Fenton, Gerald Engley, PharmD, Rachael Liu, PhD, Harry Miao, MD, Hina Jolin, Pharm D, Ashish Gautam, PhD MBA, Andrea Gallamini, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1618.
https://doi.org/10.1182/blood-2018-99-112178
Published: 2018
Journal Articles

Is Durability of Response Reported in Refractory CTCL: A Systematic Review

Mehul R Dalal, PhD, Stephen Mitchell, PhD, Conor McCloskey, PhD, Erin Zagadailov, PharmD, MS, Ashish Gautam, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5598.
https://doi.org/10.1182/blood.V130.Suppl_1.5598.5598
Published: 2017
Journal Articles

The Risk-Benefit Balance of Treatments for Hodgkin Lymphoma Reported in the Randomised and Non-Randomised Trial Setting: A Systematic Review

Mehul Dalal, PhD, Stephen Mitchell, PhD, Conor McCloskey, PhD, Erin Zagadailov, PharmD, MS, Ashish Gautam, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5605.
https://doi.org/10.1182/blood.V130.Suppl_1.5605.5605
Published: 2017
Journal Articles

Patient and Physician Preferences for Front-Line Treatment of Advanced Stage Hodgkin Lymphoma in Germany, France and the United Kingdom

Paul Broeckelmann, Aspasia Stamatoullas, MD, Suzanne McMullen, Ben Wilson, MSc, Kerstin Mueller, MSc, MA, PhD, Sarah Goring, MSc, Erin Zagadailov, PharmD, MS, Ashish Gautam, PhD, Dirk Huebner, MD, Mehul Dalal, PhD, Tim M. Illidge, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4082.
https://doi.org/10.1182/blood.V130.Suppl_1.4082.4082
Published: 2017